Clinical trials

Talking pipeline with resTORbio’s Joan Mannick

While Phase 3 trial of RTB101 for respiratory illness did not meet primary endpoint, company presses-on with Parkinson’s trial for TORC1 inhibitor: Results expected...

Alkahest’s age-related therapy enters stage 2

Age-related macular degeneration can lead to major vision loss. But researchers at Alkahest have announced they are moving forward with trials for a new...

It’s all in the numbers; small sets of numbers

AI start-up NetraMark targets $3 million seed round while identifying that an exciting repurposing candidate has potential for indication expansion into Longevity. “I won’t tell you...

Project 21 well on track

SENS Foundation business model evolves to focus on spin-outs. At the recent Longevity Forum in London, one of the keynote sessions was delivered by Dr...

Latest articles

Innovating organ-on-chip to accelerate research

BIOFABICS brings custom design tools to biofabrication. While still in its infancy, organ-on-chip (OOC) technology is quickly becoming a key growth segment in the Longevity...

Cardiff University and Ervaxx turn to the dark side

Cardiff University is looking to Ervaxx and their Dark Antigens to build on research which could lead to a universal cancer treatment. Cardiff University’s world...

Young blood back on the menu

Exclusive interview: Ambrosia getting back to business after FDA warning. Research has demonstrated that giving old mice blood transfusions from younger mice shows signs of...

Precious nano metals hold key to new treatments

Metallic nanotechnology may turn out to be the most precious way to utilise metals, at least when it comes to increasing healthspan and lifespan. When...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.